HonorHealth Research Institute’s Post

Combination targeted treatment produces lasting remissions in people with resistant aggressive B-cell lymphoma https://lnkd.in/ewv3jJYs

🌟 Exciting Developments in Hodgkin's Lymphoma Treatment 🌟 Here is some encouraging news for those affected by Hodgkin's lymphoma. Recent advances in treatment are bringing new hope and possibilities for patients and their families. Innovative therapies, including targeted treatments and immunotherapies, are showing remarkable results in improving survival rates and quality of life. These breakthroughs are a testament to the power of research, collaboration, and dedication in the medical field. As the world continues to make strides in understanding and combating this disease, let's take a moment to recognize the resilience of those battling Hodgkin's lymphoma and the tireless efforts of healthcare professionals and researchers. Together, we are moving closer to a future where Hodgkin's lymphoma is not just treatable but curable. Let's keep pushing the boundaries of what's possible! #HealthcareInnovation #LymphomaAwareness #MedicalResearch #HopeForACure #SMO #SCLAManagemnt Read more about these strides in combating this disease: https://lnkd.in/gGM3gXjJ

Combination targeted treatment produces lasting remissions in people with resistant aggressive B-cell lymphoma https://lnkd.in/ewv3jJYs

Combination targeted treatment produces lasting remissions in people with resistant aggressive B-cell lymphoma https://lnkd.in/ewv3jJYs

Combination targeted treatment produces lasting remissions in people with resistant aggressive B-cell lymphoma https://lnkd.in/ewv3jJYs

In this interview, Steve Kalloger MSc, Lymphoma Coalition, shares the results from the Lymphoma Coalition’s 2022 Global Patient Survey regarding therapeutic utilization trends among patients with chronic lymphocytic leukemia (CLL). These findings were presented at the 2024 ASCO Annual Meeting. "We advocate for the propagation of novel therapeutic strategies that are both efficacious and preserve health-related quality of life (HRQoL) across the globe. Although this data is 2 years old, our findings demonstrate that there is some heterogeneity in how CLL is treated across geographic regions," said Kalloger. Read the full interview here: https://lnkd.in/d49CHhCK #JournalOfClinicalPathways #CLL #ChronicLymphcyticLeukemia #ASCO2024

A very HAPPY FRIDAY indeed - More positive news from the CAR-T world, this time coming from BMS! The FDA has approved their CAR-T treatment, Breyanzi, for chronic lymphocytic leukemia and small lymphocytic leukemia. This approval comes ahead of an advisory committee meeting for Abecma, another CAR-T therapy. This milestone underscores the increasing recognition of CAR-T therapies and their potential to save lives. BMS is also seeking approval for Breyanzi in follicular lymphoma and mantle cell lymphoma, demonstrating a commitment to expanding treatment options. The future of CAR-T therapies is bright, with ongoing research aimed at making these revolutionary treatments accessible to more patients. #CAR-T #FDAApproval #Breyanzi https://lnkd.in/esKnPEbu

Join us today at ISPOR 2024 for two insightful poster presentations led by Eli Lilly and Company that use ConcertAI’s Mantle Cell Lymphoma Custom data. The first presentation will delve into the "Budget Impact of Pirtobrutinib for Patients With Mantle Cell Lymphoma (MCL) or Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) in the United States (US)." By focusing on the objectives of Pirtobrutinib, a non-covalent BTK inhibitor with FDA approval for MCL and CLL/SLL patients, Lilly’s budget impact model estimates the introduction of pirtobrutinib as a treatment option in the US. The results revealed minimal budget impact for these patient populations, largely due to the small eligible patient numbers. Learn more at: https://hubs.ly/Q02w02z40 The second presentation is on "Proportional Randomization Method to Identify Index Line of Therapy in Externally Controlled Trials." This innovative method, validated to determine the index line of therapy for patients in external control arms in externally controlled trials, aims to balance LOT distribution between treatment and ECA for more accurate results. Using ConcertAI Oncology Dataset for MCL, the research demonstrated effective identification of index LOT for ECA patients, with potential implications for future ECT use. This research has the power to enhance trial design and ultimately improve patient outcomes. Learn more at: https://hubs.ly/Q02w03t70 #ISPOR2024 #MantleCellLymphoma #LillyResearchI #HealthcareInnovation

CAR-T therapy for multiple sclerosis enters clinical trials: T-cells engineered to produce proteins called chimeric antigen receptors (CARs), enabling them to bind to cell surface epitopes like CD-19, can be re-infused into the person they came from to seek out and destroy their target, like B-cells. Besides 6 approved CAR-T therapies for the treatment of hematological diseases, such as B-cell acute lymphoblastic leukemia (ALL), B-cell non-Hodgkin lymphoma (NHL), follicular lymphoma, mantle cell lymphoma, and multiple lymphoma, more recent clinical data have shown promising data for the treatment of autoimmune diseases, such as systemic lupus erythematosus (SLE), myasthenia gravis (MG) and multiple sclerosis (MS).  Assuming continuation of positive news coming from clinical trials, this will enable new hope for patients with severe forms of autoimmune diseases. Hopefully, novel technologies for automated production and new formats such as allogeneic transplantation and iPSC derived cells will address the current challenges associated with scalability and cost of production. https://lnkd.in/ekMXWnnk https://lnkd.in/ei-4_YQu https://lnkd.in/eKTjBgRz https://lnkd.in/e28xJAz9 https://lnkd.in/eZadcdgT https://lnkd.in/eZwsf2WB https://lnkd.in/e_mXJ9ST https://lnkd.in/eqdXRNRE